Luo Q, Lao C, Huang C, Xia Y, Ma W, Liu W
Biol Trace Elem Res. 2020; 199(3):1027-1036.
PMID: 32468223
DOI: 10.1007/s12011-020-02218-4.
Huang C, Ma W, Luo Q, Shi L, Xia Y, Lao C
Aging (Albany NY). 2019; 11(21):9846-9861.
PMID: 31699955
PMC: 6874424.
DOI: 10.18632/aging.102433.
Serra Varela J, Pecceu E, Handel I, Lawrence J
Vet Med Sci. 2017; 2(4):266-280.
PMID: 29067202
PMC: 5645846.
DOI: 10.1002/vms3.42.
Chang S, Chang C, Lin Y, Lian I, Fann C
J Food Drug Anal. 2017; 22(4):556-562.
PMID: 28911474
PMC: 9355001.
DOI: 10.1016/j.jfda.2013.12.004.
Au K, Satterlee A, Min Y, Tian X, Kim Y, Caster J
Biomaterials. 2016; 82:178-93.
PMID: 26763733
PMC: 4728024.
DOI: 10.1016/j.biomaterials.2015.12.018.
Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.
Repetto-Llamazares A, Larsen R, Patzke S, Fleten K, Didierlaurent D, Pichard A
PLoS One. 2015; 10(6):e0128816.
PMID: 26066655
PMC: 4466226.
DOI: 10.1371/journal.pone.0128816.
Species differences in tumour responses to cancer chemotherapy.
Lawrence J, Cameron D, Argyle D
Philos Trans R Soc Lond B Biol Sci. 2015; 370(1673).
PMID: 26056373
PMC: 4581034.
DOI: 10.1098/rstb.2014.0233.
Intravenous and subcutaneous toxicity and absorption kinetics in mice and dogs of the antileishmanial triterpene saponin PX-6518.
Maes L
Molecules. 2013; 18(4):4803-15.
PMID: 23609628
PMC: 6269738.
DOI: 10.3390/molecules18044803.
Animal models and conserved processes.
Greek R, Rice M
Theor Biol Med Model. 2012; 9:40.
PMID: 22963674
PMC: 3533755.
DOI: 10.1186/1742-4682-9-40.
The Interactions between L-tyrosine based nanoparticles decorated with folic acid and cervical cancer cells under physiological flow.
Ditto A, Shah K, Robishaw N, Panzner M, Youngs W, Yun Y
Mol Pharm. 2012; 9(11):3089-98.
PMID: 22957928
PMC: 3518442.
DOI: 10.1021/mp300221f.
The war on cancer: have we won the battle but lost the war?.
Brennan R, Federico S, Dyer M
Oncotarget. 2010; 1(2):77-83.
PMID: 20877440
PMC: 2945373.
DOI: 10.18632/oncotarget.111.
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.
Heath E, LoRusso P, Ivy S, Rubinstein L, Christian M, Heilbrun L
J Biopharm Stat. 2009; 19(3):414-23.
PMID: 19384685
PMC: 3859298.
DOI: 10.1080/10543400902800460.
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients.
Walko C, Mcleod H
Nat Clin Pract Oncol. 2009; 6(3):153-62.
PMID: 19174777
DOI: 10.1038/ncponc1303.
A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology.
Bugelski P, Atif U, Molton S, Toeg I, Lord P, Morgan D
Pharm Res. 2001; 17(10):1265-72.
PMID: 11145233
DOI: 10.1023/a:1026495503939.
Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
Newell D, Burtles S, Fox B, Jodrell D, Connors T
Br J Cancer. 1999; 81(5):760-8.
PMID: 10555743
PMC: 2374299.
DOI: 10.1038/sj.bjc.6690761.
The clinical pharmacokinetics of cladribine.
Liliemark J
Clin Pharmacokinet. 1997; 32(2):120-31.
PMID: 9068927
DOI: 10.2165/00003088-199732020-00003.
Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer.
Mader R, Steger G, Rizovski B, Djavanmard M, Scheithauer W, Jakesz R
Br J Clin Pharmacol. 1995; 40(3):209-15.
PMID: 8527281
PMC: 1365099.
Pharmacokinetics of michellamine B, a naphthylisoquinoline alkaloid with in vitro activity against human immunodeficiency virus types 1 and 2, in the mouse and dog.
Supko J, Malspeis L
Antimicrob Agents Chemother. 1995; 39(1):9-14.
PMID: 7695336
PMC: 162476.
DOI: 10.1128/AAC.39.1.9.
Evaluation of antitumor drug side effects in small animals.
BRADNER W, Schurig J, HUFTALEN J, DOYLE G
Cancer Chemother Pharmacol. 1980; 4(2):95-101.
PMID: 7389061
DOI: 10.1007/BF00254029.
The clinical evaluation of analogs--III. Anthracyclines.
Carter S
Cancer Chemother Pharmacol. 1980; 4(1):5-10.
PMID: 7363403
DOI: 10.1007/BF00255451.